PPAR agonists (PPARα and PPARγ) have been clinically used for many years as treatments for diabetes and dyslipidemia while mixed (PPARα/δ/γ) agonists have been evaluated for efficacy against NASH (52–55). The gene discussed is PPARA; the disease is metabolic syndrome.